Gratus Capital’s AstraZeneca AZN Stock Holding History

Gratus Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,851	Closed	-$251K	–	227
2022 Q4	$251K	Hold	1,851	–	–	0.02%	204
2022 Q3	$203K	Buy	1,851 +65	+4%	+$8.25K	0.02%	194
2022 Q2	$236K	Hold	1,786	–	–	0.03%	172
2022 Q1	$237K	Hold	1,786	–	–	0.02%	188
2021 Q4	$208K	Buy	+1,786	New	+$210K	0.02%	193
2020 Q4	–	Sell	-62,376	Closed	-$6.84M	–	185
2020 Q3	$6.84M	Sell	62,376 -6,946	-10%	-$773K	1.07%	37
2020 Q2	$7.33M	Buy	+69,322	New	+$7.16M	1.24%	33

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Gratus Capital's AZN Position: Q1 2023 in Review

Gratus Capital sold out of AstraZeneca (AZN) in Q1 2023, closing a stake of 1,851 shares — an estimated $251K sold.

Gratus Capital first reported a position in AZN in Q2 2020 and held it in 7 quarters. The position peaked at $7.33M in Q2 2020. 1,055 funds tracked by Wall St. Rank hold AZN as of Q1 2023.

Gratus Capital reported no remaining AstraZeneca position as of Q1 2023 after selling out during the quarter.
Gratus Capital sold 1,851 AstraZeneca shares in Q1 2023, an estimated $251K.
Gratus Capital first reported a position in AstraZeneca in Q2 2020 and held it in 7 quarters.
Gratus Capital's AstraZeneca position peaked at $7.33M in Q2 2020.
1,055 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2023.

Based on Gratus Capital's 13F filing for Q1 2023, filed 20 Apr 2023.